Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods

Abstract

Objective The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders. The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described. Method Using a randomized, double-blind, parallel-group design at four sites, youths with EOSS (ages 8-19 years) were assigned to an 8-week acute trial of risperidone (0.5-6.0 mg/day), olanzapine (2.5-20 mg/day), or molindone (10-140 mg/day). Responders continued double-blind treatment for 44 weeks. The primary outcome measure was responder status at 8 weeks, defined by a 20% reduction in baseline Positive and Negative Symptom Scale scores plus ratings of significant improvement on the Clinical Global Impressions. Secondary outcome measures included assessments of psychopathology, functional impairment, quality of life, and medication safety. An intent-to-treat analytic plan was used. Results From February 2002 to May 2006, 476 youths were screened, 173 were further evaluated, and 119 were randomized. Several significant study modifications were required to address safety, the use of adjunctive medications, and the termination of the olanzapine treatment arm due to weight gain. Conclusions The Treatment of Early Onset Schizophrenia Spectrum Disorders Study will inform clinic…

Overview

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e3180691779

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 3

  1. Kryzhanovskaya, 2006, A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia, Schizophr Res, 81, S44
  2. National Institute of Mental Health, 1985, Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research, Psychopharmacol Bull, 21, 765
  3. Simpson, 1970, A rating scale for extrapyramidal effects, Acta Psychiatr Scand, 212, 111

Cited by

See all 90

Metadata

Authors
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., RITZ, L., ANDERSON, R., HAMER, R. M., & LIEBERMAN, J. A.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
McCLELLAN, JON
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2007-08
Volume
46
Issue
8
Pages
969-978
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2048486175
Cited by
90
References
37
Citations by year
2026: 2 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 6
FWCI
10.09
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • National Institute of Mental Health (U01MH062726, K23 MH70570, U01 MH62726, U01MH061355, U01MH61355, K23MH070570, U01MH061528, U01MH061464, U01MH61528, U01MH61464)
  • National Center for Research Resources (M01 RR00046, M01-RR 00037, M01RR000046, M01RR000037)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
antipsychotic drugs, risperidone, olanzapine, molindone, drug safety, suicidality, weight gain, adolescent psychiatry, treatment response, functional disability, quality of life
MeSH terms
Olanzapine, Adolescent, Adult, Benzodiazepines, Child, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Molindone, Schizophrenia, Time Factors, Antipsychotic Agents, Comorbidity, Age of Onset, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. https://app.cochat.ai/papers/10.1097/chi.0b013e3180691779
The paper
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., RITZ, L., ANDERSON, R., HAMER, R. M., & LIEBERMAN, J. A. (2007). Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/chi.0b013e3180691779

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.